Sphera Funds Management LTD. raised its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 65.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 248,000 shares of the biopharmaceutical company’s stock after acquiring an additional 98,000 shares during the quarter. Bristol-Myers Squibb accounts for about 2.3% of Sphera Funds Management LTD.’s portfolio, making the stock its 7th biggest holding. Sphera Funds Management LTD.’s holdings in Bristol-Myers Squibb were worth $13,819,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. First Trust Advisors LP raised its holdings in Bristol-Myers Squibb by 10.7% during the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares during the period. Toronto Dominion Bank increased its holdings in shares of Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after purchasing an additional 162,884 shares during the period. Oppenheimer & Co. Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.5% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after purchasing an additional 8,813 shares during the period. Mutual of America Capital Management LLC increased its holdings in shares of Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after purchasing an additional 3,833 shares during the period. Finally, Dividend Assets Capital LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $737,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.
In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by corporate insiders.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded down $1.05 during trading on Wednesday, reaching $60.97. The company’s stock had a trading volume of 4,758,697 shares, compared to its average volume of 8,437,080. The company has a market capitalization of $99,860.00, a PE ratio of 21.10, a P/E/G ratio of 2.37 and a beta of 1.17. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
BMY has been the topic of a number of research reports. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a report on Tuesday, September 12th. Goldman Sachs Group reiterated a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a report on Wednesday, November 1st. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Finally, Barclays increased their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $64.93.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.